出版：MarketsandMarkets（マーケッツアンドマーケッツ） 出版年月：2024年4月
Sepsis Diagnostics Market – Global Forecast To 2029
敗血症診断市場 : 技術（微生物学、PCR、免疫測定法、マイクロ流体工学、バイオマーカー）、製品（培地、試薬、機器）、方法（自動）、検査（研究室、POC）、病原体（細菌、真菌）、エンドユーザー＆地域別の規模 – 2029年までの世界予測
Sepsis Diagnostics Market Size By Technology (Microbiology, PCR, Immunoassay, microfluidics, Biomarker), Product (Media, Reagent, Instrument), Method (Automated), Test (Lab, POC), Pathogen (Bacterial, Fungal), End User & Region – Global Forecast to 2029
| ページ数 | 264 |
| 図表数 | 311 |
| 価格 | |
| シングルユーザライセンス | USD 4,950 |
| マルチユーザライセンス（5名） | USD 6,650 |
| コーポレートライセンス | USD 8,150 |
| エンタープライズサイトライセンス | USD 10,000 |
| 種別 | 英文調査報告書 |
Report Overview
The global sepsis diagnostics market is projected to reach USD 890 million by 2029 from USD 634 million in 2024, growing at a CAGR of 7.0% during the forecast period.
世界の敗血症診断市場は、2024年の6億3,400万米ドルから2029年までに8億9,000万米ドルに達すると予測されており、予測期間中に7.0%のCAGRで成長します。
The increasing number of sepsis diagnostics procedures is one of the major factors anticipated to boost market growth in the forecasting years. Additionally, the high cost of diagnostic devices affects the growth of the sepsis diagnostics market.
“The blood culture segment to hold the largest share of the market in 2024.”
Based on technology, sepsis diagnostics is segmented into blood culture, immunoassays, molecular diagnostics, flow cytometry, microfluidics, and biomarkers. Blood culture segment is expected to dominate the sepsis diagnostics market during the forecast period. With the increasing sepsis incidences and this technique be the standard technique leading to the growth of this market segment.
“The blood culture media segment to hold the largest share of the market in 2024.”
Based on product, the sepsis diagnostics market is segmented into mesh, sutures, mesh fixator, and other products. The sepsis diagnostics market is expected to be dominated by blood culture media segment during the forecast period. The blood culture media is expected to grow due to their affordable prices as compared to other sepsis diagnostics products.
“The bacterial sepsis segment to hold the largest share of the market in 2024.”
Based on the pathogen type, the sepsis diagnostics market is segmented into bacterial sepsis, fungal sepsis, and other pathogens. The bacterial sepsis segment is further divided into gram-positive bacteria sepsis and gram-negative bacteria sepsis. The bacterial sepsis segment is estimated to hold the largest market share of the sepsis diagnostics market during the forecast period. Rising number of bacterial sepsis cases leads to the increasing growth of the segment in the market.
“The hospitals & speciality clinics segment to hold the largest share of the market in 2024.”
The end user market is segmented into hospitals & speciality clinics, pathology & reference laboratories, and research laboratories, academic institutes & CROs . Hospitals & speciality clinics accounted for the largest share of the global sepsis diagnostics market in 2023 during the forecasted years. This can be attributed to the high patient inflow in this care setting. Only hospitals and clinics can provide the care and monitoring required in exceptionally severe cases, which also accounts for their dominance in the market.
“The market in the North America region is expected to hold a significant market share for sepsis diagnostics in 2022.”
The sepsis diagnostics market covers five key geographies—North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. In 2023, a significant market share for sepsis diagnostics was held by the market in the North American region, comprising the US and Canada. The strong demand for and adoption of sepsis diagnostics in the US led to the growth of the Sepsis diagnostics market in this region.
A breakdown of the primary participants referred to for this report is provided below:
• By Company Type: Tier 1– 25%, Tier 2– 30%, and Tier 3– 45%
• By Designation: C-level– 26%, Directors– 30%, and Others– 44%
• By Region: North America– 40%, Europe– 31%, Asia Pacific– 20%, Latin America- 6%, MEA- 3%
The prominent players in the sepsis diagnostics market are bioMérieux S.A. (France), Becton Dickinson and Company (US), Danaher Corporation (US), T2 Biosystems (US), QIAGEN N.V. (Germany), F. Hoffmann-La Roche Ltd (Switzerland), Thermo Fisher Scientific (US), Bruker Corporation (US), Abbott Laboratories (US), among others.
Research Coverage
This report studies the sepsis diagnostics market based on technology, product, method, pathogen type, test type, end user, and region. It also covers the factors affecting market growth, analyzes the various opportunities and challenges in the market, and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five main regions (and the respective countries in these regions).
Reasons to Buy the Report
The report will enable established firms as well as entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to garner a larger market share. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their market presence.
This report provides insights on the following pointers:
• Analysis of key drivers (High incidence of sepsis, Rising incidence of hospital-acquired infections (HAIs), Growing funding for sepsis-related research), restraints (High cost of automated diagnostic devices), opportunities (Development of rapid diagnostic/POC techniques for early sepsis diagnosis, Evolution of novel biomarkers for sepsis diagnosis, Growth Opportunities in emerging economies), and challenges (Lack of awareness and limited protocols for sepsis diagnosis, Shortage of skilled healthcare professionals) influencing the growth of the sepsis diagnostics market
• Market Penetration: Comprehensive information on the product portfolios offered by the top players in the sepsis diagnostics market
• Service Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and service developments in the sepsis diagnostics market
• Market Development: Comprehensive information on lucrative emerging regions
• Market Diversification: Exhaustive information about new services, growing geographies, and recent developments in the sepsis diagnostics market
• Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and services of the leading market players.
Table of Contents
1 INTRODUCTION 39
1.1 STUDY OBJECTIVES 39
1.2 MARKET DEFINITION 39
1.2.1 INCLUSIONS AND EXCLUSIONS OF STUDY 40
1.3 STUDY SCOPE 41
1.3.1 MARKETS COVERED 41
1.3.2 GEOGRAPHIES COVERED 41
1.3.3 YEARS CONSIDERED 42
1.4 CURRENCY 42
1.5 MARKET STAKEHOLDERS 42
1.6 SUMMARY OF CHANGES 43
1.6.1 RECESSION IMPACT 43
2 RESEARCH METHODOLOGY 45
2.1 RESEARCH DATA 45
FIGURE 1 RESEARCH DESIGN 45
2.1.1 SECONDARY DATA 46
2.1.1.1 Indicative list of secondary sources 47
2.1.2 PRIMARY DATA 47
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 48
2.2 MARKET ESTIMATION METHODOLOGY 49
FIGURE 3 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 49
2.2.1 REVENUE MAPPING-BASED MARKET ESTIMATION 50
FIGURE 4 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS (2023) 51
2.2.2 APPROACH 1: PROCEDURE-BASED MARKET ESTIMATION 51
FIGURE 5 MARKET SIZE ESTIMATION: SEPSIS DIAGNOSTICS MARKET BASED ON PROCEDURE METHODOLOGY 51
2.2.3 APPROACH 2: END USER-BASED MARKET ESTIMATION 52
FIGURE 6 MARKET SIZE ESTIMATION METHODOLOGY: SEPSIS DIAGNOSTICS MARKET 52
2.2.4 PRIMARY RESEARCH VALIDATION 53
2.3 DATA TRIANGULATION 54
FIGURE 7 DATA TRIANGULATION METHODOLOGY 54
2.4 RESEARCH ASSUMPTIONS 55
2.5 RESEARCH LIMITATIONS 55
2.6 RISK ASSESSMENT 56
TABLE 1 SEPSIS DIAGNOSTICS MARKET: RISK ASSESSMENT ANALYSIS 56
2.6.1 IMPACT OF RECESSION ON SEPSIS DIAGNOSTICS MARKET 56
3 EXECUTIVE SUMMARY 57
FIGURE 8 SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2024 VS. 2029 (USD MILLION) 57
FIGURE 9 SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024 VS. 2029 (USD MILLION) 58
FIGURE 10 SEPSIS DIAGNOSTICS MARKET SHARE, BY METHOD, 2024 VS. 2029 58
FIGURE 11 SEPSIS DIAGNOSTICS MARKET SHARE, BY TEST TYPE, 2024 VS. 2029 59
FIGURE 12 SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2024 VS. 2029 (USD MILLION) 59
FIGURE 13 SEPSIS DIAGNOSTICS MARKET SHARE, BY END USER, 2024 VS. 2029 60
FIGURE 14 GEOGRAPHICAL SNAPSHOT OF SEPSIS DIAGNOSTICS MARKET 60
4 PREMIUM INSIGHTS 62
4.1 SEPSIS DIAGNOSTICS MARKET OVERVIEW 62
FIGURE 15 HIGH INCIDENCE OF SEPSIS TO DRIVE MARKET 62
4.2 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT AND COUNTRY (2023) 63
FIGURE 16 BLOOD CULTURE MEDIA SEGMENT ACCOUNTED FOR LARGEST SHARE OF ASIA PACIFIC MARKET IN 2023 63
4.3 SEPSIS DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 64
FIGURE 17 CHINA TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 64
4.4 SEPSIS DIAGNOSTICS MARKET: REGIONAL MIX, 2022–2029 (USD MILLION) 64
FIGURE 18 NORTH AMERICA WILL CONTINUE TO DOMINATE SEPSIS DIAGNOSTICS MARKET DURING FORECAST PERIOD 64
5 MARKET OVERVIEW 65
5.1 INTRODUCTION 65
5.2 MARKET DYNAMICS 65
FIGURE 19 SEPSIS DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 65
5.2.1 DRIVERS 66
5.2.1.1 High incidence of sepsis 66
5.2.1.2 Rising incidence of HAIs 67
5.2.1.3 Growing funding for sepsis-related research 67
5.2.2 RESTRAINTS 68
5.2.2.1 High cost of automated diagnostic devices 68
5.2.3 OPPORTUNITIES 68
5.2.3.1 Development of rapid diagnostic/POC techniques for early sepsis diagnosis 68
5.2.3.2 Evolution of novel biomarkers for sepsis diagnosis 68
5.2.3.3 Growth opportunities in emerging economies 69
5.2.4 CHALLENGES 69
5.2.4.1 Lack of awareness and limited protocols for sepsis diagnosis 69
5.2.4.2 Shortage of skilled healthcare professionals 70
5.3 REGULATORY SCENARIO 70
5.3.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 70
TABLE 2 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AUTHORITIES, AND OTHER ORGANIZATIONS 70
TABLE 3 EUROPE: REGULATORY BODIES, GOVERNMENT AUTHORITIES, AND OTHER ORGANIZATIONS 71
TABLE 4 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AUTHORITIES, AND OTHER ORGANIZATIONS 71
TABLE 5 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AUTHORITIES, AND OTHER ORGANIZATIONS 72
TABLE 6 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AUTHORITIES, AND OTHER ORGANIZATIONS 72
5.3.2 KEY REGULATORY GUIDELINES 72
5.3.2.1 North America 72
5.3.2.1.1 US 72
5.3.2.1.2 Canada 73
5.3.2.2 Europe 73
5.3.2.3 Asia Pacific 73
5.3.2.3.1 China 73
5.3.2.3.2 Japan 74
5.3.2.3.3 India 74
5.3.2.4 Latin America 74
5.4 REIMBURSEMENT SCENARIO 74
TABLE 7 MS DRG PAYMENT CALCULATED FOR NATIONAL PROVIDERS 75
5.5 VALUE CHAIN ANALYSIS 75
5.5.1 RESEARCH & DEVELOPMENT 76
5.5.2 PROCUREMENT AND PRODUCT DEVELOPMENT 76
5.5.3 MARKETING, SALES, AND DISTRIBUTION 76
FIGURE 20 VALUE CHAIN ANALYSIS 76
5.6 SUPPLY CHAIN ANALYSIS 77
5.6.1 PROMINENT COMPANIES 77
5.6.2 SMALL & MEDIUM-SIZED ENTERPRISES 77
5.6.3 END USERS 77
FIGURE 21 SUPPLY CHAIN ANALYSIS 77
5.7 ECOSYSTEM COVERAGE 78
FIGURE 22 MARKET MAP 78
5.8 PORTER’S FIVE FORCES ANALYSIS 79
TABLE 8 SEPSIS DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS 79
5.8.1 INTENSITY OF COMPETITIVE RIVALRY 79
5.8.2 BARGAINING POWER OF BUYERS 79
5.8.3 BARGAINING POWER OF SUPPLIERS 79
5.8.4 THREAT OF NEW ENTRANTS 80
5.8.5 THREAT OF SUBSTITUTES 80
5.9 TRADE DATA ANALYSIS 80
TABLE 9 IMPORT DATA FOR HERNIA MESH (HS CODE 902190), BY COUNTRY, 2018–2022 (USD) 80
TABLE 10 EXPORT DATA FOR HERNIA MESHES (HS CODE 902190), BY COUNTRY, 2018–2022 (USD) 81
5.10 PATENT ANALYSIS 82
FIGURE 23 PATENT ANALYSIS 82
5.11 PRICING ANALYSIS 83
5.11.1 AVERAGE SELLING PRICE TREND, BY REGION 83
TABLE 11 SEPSIS DIAGNOSTICS PRICING ANALYSIS, BY REGION, 2023 (USD) 83
5.11.2 AVERAGE SELLING PRICE TREND, BY KEY PLAYER 83
TABLE 12 HERNIA REPAIR PRICING ANALYSIS, BY KEY PLAYER, 2023 (USD) 83
5.12 TECHNOLOGY ANALYSIS 84
5.12.1 KEY TECHNOLOGIES 84
5.12.1.1 Biomarkers 84
5.12.1.2 Microfluidics 84
5.12.2 COMPLIMENTARY TECHNOLOGIES 84
5.12.2.1 Genomics and Transcriptomics 84
5.12.2.2 Machine Learning and Artificial Intelligence (AI) 84
5.12.3 ADJACENT TECHNOLOGIES 84
5.12.3.1 Nanotechnology Sensors 84
5.12.3.2 Medical Imaging 84
5.12.3.3 Digital Health Solutions 84
5.13 KEY CONFERENCES AND EVENTS IN 2023–2024 85
TABLE 13 SEPSIS DIAGNOSTICS: LIST OF MAJOR CONFERENCES & EVENTS 85
5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS 86
FIGURE 24 EMERGING TRENDS AND OPPORTUNITIES AFFECTING FUTURE REVENUE MIX 86
5.15 SEPSIS DIAGNOSTICS MARKET: RECESSION IMPACT 86
5.16 KEY STAKEHOLDERS AND BUYING CRITERIA 87
5.16.1 KEY STAKEHOLDERS 87
FIGURE 25 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS 87
TABLE 14 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR PRODUCT SEGMENTS (%) 87
5.16.2 KEY BUYING CRITERIA 87
FIGURE 26 KEY BUYING CRITERIA FOR SEPSIS DIAGNOSTIC PRODUCTS 87
TABLE 15 KEY BUYING CRITERIA FOR SEPSIS DIAGNOSTIC PRODUCTS 88
5.17 UNMET NEEDS AND KEY PAIN POINTS 88
TABLE 16 SEPSIS DIAGNOSTICS MARKET: UNMET CUSTOMER NEEDS AND KEY PAIN POINTS 88
5.18 INVESTMENT SCENARIO 89
FIGURE 27 NUMBER OF INVESTOR DEALS IN SEPSIS DIAGNOSTICS MARKET, BY KEY PLAYER, 2018–2022 89
FIGURE 28 VALUE OF INVESTOR DEALS IN SEPSIS DIAGNOSTICS MARKET, BY KEY PLAYER, 2018–2022 (USD MILLION) 89
6 SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY 90
6.1 INTRODUCTION 91
TABLE 17 SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 91
6.2 BLOOD CULTURE (MICROBIOLOGY TESTING) 91
6.2.1 MOST COMMONLY ADOPTED TECHNOLOGY FOR SEPSIS DIAGNOSTICS 91
TABLE 18 BLOOD CULTURE MARKET, BY REGION, 2022–2029 (USD MILLION) 92
TABLE 19 BLOOD CULTURE MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 92
TABLE 20 BLOOD CULTURE MARKET, BY METHOD, 2022–2029 (USD MILLION) 92
TABLE 21 BLOOD CULTURE MARKET, BY PATHOGEN TYPE, 2022–2029 (USD MILLION) 93
TABLE 22 BLOOD CULTURE MARKET FOR BACTERIAL SEPSIS, BY TYPE, 2022–2029 (USD MILLION) 93
TABLE 23 BLOOD CULTURE MARKET, BY TEST TYPE, 2022–2029 (USD MILLION) 93
TABLE 24 BLOOD CULTURE MARKET, BY END USER, 2022–2029 (USD MILLION) 94
6.3 IMMUNOASSAYS 94
6.3.1 RISING PRODUCT DEVELOPMENT BY MAJOR PLAYERS TO SUPPORT MARKET GROWTH 94
TABLE 25 IMMUNOASSAYS MARKET, BY REGION, 2022–2029 (USD MILLION) 95
TABLE 26 IMMUNOASSAYS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 95
TABLE 27 IMMUNOASSAYS MARKET, BY METHOD, 2022–2029 (USD MILLION) 95
TABLE 28 IMMUNOASSAYS MARKET, BY PATHOGEN TYPE, 2022–2029 (USD MILLION) 96
TABLE 29 IMMUNOASSAYS MARKET FOR BACTERIAL SEPSIS, BY TYPE, 2022–2029 (USD MILLION) 96
TABLE 30 IMMUNOASSAYS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION) 96
TABLE 31 IMMUNOASSAYS MARKET, BY END USER, 2022–2029 (USD MILLION) 97
6.4 MOLECULAR DIAGNOSTICS 97
TABLE 32 MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD MILLION) 97
TABLE 33 MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2022–2029 (USD MILLION) 98
TABLE 34 MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 98
TABLE 35 MOLECULAR DIAGNOSTICS MARKET, BY METHOD, 2022–2029 (USD MILLION) 98
TABLE 36 MOLECULAR DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2022–2029 (USD MILLION) 99
TABLE 37 MOLECULAR DIAGNOSTICS MARKET FOR BACTERIAL SEPSIS, BY TYPE, 2022–2029 (USD MILLION) 99
TABLE 38 MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION) 99
TABLE 39 MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 100
6.4.1 POLYMERASE CHAIN REACTION 100
6.4.1.1 Quick turnaround time and technological advancements to propel market 100
TABLE 40 POLYMERASE CHAIN REACTION MARKET, BY REGION, 2022–2029 (USD MILLION) 100
6.4.2 MICROARRAYS 101
6.4.2.1 Simultaneous analysis capabilities & accuracy to boost adoption 101
TABLE 41 MICROARRAYS MARKET, BY REGION, 2022–2029 (USD MILLION) 101
6.4.3 PEPTIDE NUCLEIC ACID-FLUORESCENT IN SITU HYBRIDIZATION 101
6.4.3.1 Enables rapid diagnosis of bloodstream infections 101
TABLE 42 PEPTIDE NUCLEIC ACID-FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY REGION, 2022–2029 (USD MILLION) 102
6.4.4 DNA SEQUENCING 102
6.4.4.1 Shortens time for sepsis diagnosis 102
TABLE 43 DNA SEQUENCING MARKET, BY REGION, 2022–2029 (USD MILLION) 103
6.5 FLOW CYTOMETRY 103
6.5.1 LACK OF STANDARDIZED PROTOCOLS—KEY FACTOR RESTRAINING MARKET GROWTH 103
TABLE 44 FLOW CYTOMETRY MARKET, BY REGION, 2022–2029 (USD MILLION) 103
TABLE 45 FLOW CYTOMETRY MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 104
TABLE 46 FLOW CYTOMETRY MARKET, BY METHOD, 2022–2029 (USD MILLION) 104
TABLE 47 FLOW CYTOMETRY MARKET, BY PATHOGEN TYPE, 2022–2029 (USD MILLION) 104
TABLE 48 FLOW CYTOMETRY MARKET FOR BACTERIAL SEPSIS, BY TYPE, 2022–2029 (USD MILLION) 105
TABLE 49 FLOW CYTOMETRY MARKET, BY TEST TYPE, 2022–2029 (USD MILLION) 105
TABLE 50 FLOW CYTOMETRY MARKET, BY END USER, 2022–2029 (USD MILLION) 105
6.6 MICROFLUIDICS 106
6.6.1 RISING ADOPTION OF ADVANCED AND RAPID TESTING TO DRIVE GROWTH 106
TABLE 51 MICROFLUIDICS MARKET, BY REGION, 2022–2029 (USD MILLION) 106
TABLE 52 MICROFLUIDICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 107
TABLE 53 MICROFLUIDICS MARKET, BY METHOD, 2022–2029 (USD MILLION) 107
TABLE 54 MICROFLUIDICS MARKET, BY PATHOGEN TYPE, 2022–2029 (USD MILLION) 107
TABLE 55 MICROFLUIDICS MARKET FOR BACTERIAL SEPSIS, BY TYPE, 2022–2029 (USD MILLION) 108
TABLE 56 MICROFLUIDICS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION) 108
TABLE 57 MICROFLUIDICS MARKET, BY END USER, 2022–2029 (USD MILLION) 108
6.7 BIOMARKERS 109
6.7.1 RESEARCH & DEVELOPMENT FOR DISCOVERY OF NOVEL BIOMARKERS TO DRIVE GROWTH 109
TABLE 58 BIOMARKERS MARKET, BY REGION, 2022–2029 (USD MILLION) 109
TABLE 59 BIOMARKERS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 110
TABLE 60 BIOMARKERS MARKET, BY METHOD, 2022–2029 (USD MILLION) 110
TABLE 61 BIOMARKERS MARKET, BY PATHOGEN TYPE, 2022–2029 (USD MILLION) 110
TABLE 62 BIOMARKERS MARKET FOR BACTERIAL SEPSIS, BY TYPE, 2022–2029 (USD MILLION) 111
TABLE 63 BIOMARKERS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION) 111
TABLE 64 BIOMARKERS MARKET, BY END USER, 2022–2029 (USD MILLION) 111
7 SEPSIS DIAGNOSTICS MARKET, BY PRODUCT 112
7.1 INTRODUCTION 113
TABLE 65 SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 113
7.2 BLOOD CULTURE MEDIA 113
7.2.1 RISE IN BLOODSTREAM INFECTIONS TO DRIVE GROWTH 113
TABLE 66 SEPSIS DIAGNOSTIC BLOOD CULTURE MEDIA MARKET, BY REGION, 2022–2029 (USD MILLION) 114
7.3 ASSAYS & REAGENT KITS 114
7.3.1 ASSAYS BETTER ENABLE ANALYSIS OF PATIENT SAMPLES FOR DISEASE DIAGNOSIS 114
TABLE 67 SEPSIS DIAGNOSTIC ASSAYS & REAGENT KITS MARKET, BY REGION, 2022–2029 (USD MILLION) 115
7.4 INSTRUMENTS 115
7.4.1 INCREASING INCLINATION TOWARD RAPID DIAGNOSTIC SYSTEMS TO DRIVE MARKET 115
TABLE 68 SEPSIS DIAGNOSTIC INSTRUMENTS MARKET, BY REGION, 2022–2029 (USD MILLION) 116
7.5 SOFTWARE 116
7.5.1 INCREASING USE OF AUTOMATED INSTRUMENTS TO DRIVE DEMAND FOR SOFTWARE 116
TABLE 69 SEPSIS DIAGNOSTIC SOFTWARE MARKET, BY REGION, 2022–2029 (USD MILLION) 117
8 SEPSIS DIAGNOSTICS MARKET, BY METHOD 118
8.1 INTRODUCTION 119
TABLE 70 SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2022–2029 (USD MILLION) 119
8.2 CONVENTIONAL DIAGNOSTICS 119
8.2.1 EASE OF USE AND LOW COST TO PROPEL MARKET GROWTH 119
TABLE 71 CONVENTIONAL SEPSIS DIAGNOSTICS MARKET, BY REGION, 2022–2029 (USD MILLION) 120
8.3 AUTOMATED DIAGNOSTICS 120
8.3.1 ACCURACY AND QUICK TURNAROUND TIME TO DRIVE ADOPTION 120
TABLE 72 AUTOMATED SEPSIS DIAGNOSTICS MARKET, BY REGION, 2022–2029 (USD MILLION) 121
9 SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE 122
9.1 INTRODUCTION 123
TABLE 73 SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2022–2029 (USD MILLION) 123
9.2 BACTERIAL SEPSIS 123
TABLE 74 BACTERIAL SEPSIS MARKET, BY TYPE, 2022–2029 (USD MILLION) 123
TABLE 75 BACTERIAL SEPSIS MARKET, BY REGION, 2022–2029 (USD MILLION) 124
9.2.1 GRAM-NEGATIVE BACTERIAL SEPSIS 124
9.2.1.1 Increasing demand for sepsis diagnostic tests to drive market 124
TABLE 76 GRAM-NEGATIVE BACTERIAL CAUSES IN ADULTS 125
TABLE 77 GRAM-NEGATIVE BACTERIAL SEPSIS MARKET, BY REGION, 2022–2029 (USD MILLION) 125
9.2.2 GRAM-POSITIVE BACTERIAL SEPSIS 125
9.2.2.1 Increasing incidence of gram-positive nosocomial infections to propel market 125
TABLE 78 GRAM-POSITIVE BACTERIAL CAUSES IN ADULTS 126
TABLE 79 GRAM-POSITIVE BACTERIAL SEPSIS MARKET, BY REGION, 2022–2029 (USD MILLION) 126
9.3 FUNGAL SEPSIS 126
9.3.1 RISING INCIDENCE OF FUNGAL INFECTIONS TO PROPEL MARKET 126
TABLE 80 FUNGAL SEPSIS MARKET, BY REGION, 2022–2029 (USD MILLION) 127
9.4 OTHER PATHOGEN TYPES 127
TABLE 81 OTHER PATHOGEN TYPES MARKET, BY REGION, 2022–2029 (USD MILLION) 127
10 SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE 128
10.1 INTRODUCTION 129
TABLE 82 SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION) 129
10.2 LABORATORY TESTS 129
10.2.1 MOST COMMON AND PREFERRED MODE OF TESTING 129
TABLE 83 LABORATORY SEPSIS DIAGNOSTIC TESTS MARKET, BY REGION, 2022–2029 (USD MILLION) 130
10.3 POINT-OF-CARE TESTS 130
10.3.1 INCREASING DEVELOPMENT OF NOVEL POC DIAGNOSTICS TO SUPPORT MARKET GROWTH 130
TABLE 84 POINT-OF-CARE SEPSIS DIAGNOSTIC TESTS MARKET, BY REGION, 2022–2029 (USD MILLION) 131
11 SEPSIS DIAGNOSTICS MARKET, BY END USER 132
11.1 INTRODUCTION 133
TABLE 85 SEPSIS DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 133
11.2 HOSPITALS AND SPECIALTY CLINICS 133
11.2.1 INCREASING ADOPTION OF SEPSIS DIAGNOSTIC PRODUCTS BY IN-HOUSE HOSPITAL LABS TO DRIVE MARKET 133
TABLE 86 SEPSIS DIAGNOSTICS MARKET FOR HOSPITALS AND SPECIALTY CLINICS, BY REGION, 2022–2029 (USD MILLION) 134
11.3 PATHOLOGY AND REFERENCE LABORATORIES 134
11.3.1 INDEPENDENT LABORATORIES OFFER AFFORDABLE AND EFFICIENT DIAGNOSTIC SERVICES 134
TABLE 87 SEPSIS DIAGNOSTICS MARKET FOR PATHOLOGY AND REFERENCE LABORATORIES, BY REGION, 2022–2029 (USD MILLION) 135
11.4 RESEARCH LABORATORIES, ACADEMIC INSTITUTES, AND CROS 135
11.4.1 GOVERNMENT SUPPORT AND RISING AWARENESS FOR EARLY SEPSIS DETECTION TO DRIVE GROWTH 135
TABLE 88 SEPSIS DIAGNOSTICS MARKET FOR RESEARCH LABORATORIES, ACADEMIC INSTITUTES, AND CROS, BY REGION, 2022–2029 (USD MILLION) 136
12 SEPSIS DIAGNOSTICS MARKET, BY REGION 137
12.1 INTRODUCTION 138
TABLE 89 SEPSIS DIAGNOSTICS MARKET, BY REGION, 2022–2029 (USD MILLION) 138
12.2 NORTH AMERICA 138
FIGURE 29 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET SNAPSHOT 139
TABLE 90 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 139
TABLE 91 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 140
TABLE 92 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD MILLION) 140
TABLE 93 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 141
TABLE 94 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2022–2029 (USD MILLION) 141
TABLE 95 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2022–2029 (USD MILLION) 141
TABLE 96 NORTH AMERICA: BACTERIAL SEPSIS MARKET, BY TYPE, 2022–2029 (USD MILLION) 142
TABLE 97 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION) 142
TABLE 98 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 142
12.3 RECESSION IMPACT ON NORTH AMERICAN SEPSIS DIAGNOSTICS MARKET 143
12.3.1 US 143
12.3.1.1 Rising incidence of HAIs to drive demand 143
TABLE 99 US: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 144
TABLE 100 US: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD MILLION) 144
12.3.2 CANADA 145
12.3.2.1 Growing availability of sepsis diagnostic products to support market growth 145
TABLE 101 CANADA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 146
TABLE 102 CANADA: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD MILLION) 146
12.4 EUROPE 146
TABLE 103 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 147
TABLE 104 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 147
TABLE 105 EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD MILLION) 148
TABLE 106 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 148
TABLE 107 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2022–2029 (USD MILLION) 148
TABLE 108 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2022–2029 (USD MILLION) 149
TABLE 109 EUROPE: BACTERIAL SEPSIS MARKET, BY TYPE, 2022–2029 (USD MILLION) 149
TABLE 110 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION) 149
TABLE 111 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 150
12.4.1 RECESSION IMPACT ON EUROPEAN SEPSIS DIAGNOSTICS MARKET 150
12.4.2 GERMANY 150
12.4.2.1 Adoption of technologically advanced diagnostic products to drive market 150
TABLE 112 GERMANY: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 151
TABLE 113 GERMANY: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD MILLION) 152
12.4.3 UK 152
12.4.3.1 Stringent government regulations to drive market growth 152
TABLE 114 UK: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 153
TABLE 115 UK: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD MILLION) 153
12.4.4 FRANCE 153
12.4.4.1 High incidence of sepsis to propel growth 153
TABLE 116 FRANCE: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 154
TABLE 117 FRANCE: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD MILLION) 154
12.4.5 ITALY 154
12.4.5.1 Supportive government initiatives for raising awareness on sepsis to drive market 154
TABLE 118 ITALY: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 155
TABLE 119 ITALY: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD MILLION) 155
12.4.6 SPAIN 155
12.4.6.1 Rising awareness for early diagnosis of propel market 155
TABLE 120 SPAIN: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 156
TABLE 121 SPAIN: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD MILLION) 156
12.4.7 REST OF EUROPE 157
TABLE 122 REST OF EUROPE: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 157
TABLE 123 REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD MILLION) 157
12.5 ASIA PACIFIC 158
FIGURE 30 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET SNAPSHOT 158
TABLE 124 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 159
TABLE 125 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 159
TABLE 126 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD MILLION) 160
TABLE 127 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 160
TABLE 128 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2022–2029 (USD MILLION) 160
TABLE 129 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2022–2029 (USD MILLION) 161
TABLE 130 ASIA PACIFIC: BACTERIAL SEPSIS MARKET, BY TYPE, 2022–2029 (USD MILLION) 161
TABLE 131 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION) 161
TABLE 132 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 162
12.5.1 RECESSION IMPACT ON ASIA PACIFIC SEPSIS DIAGNOSTICS MARKET 162
12.5.2 JAPAN 162
12.5.2.1 Rising incidence of pneumonia and infectious diseases to support market growth 162
TABLE 133 JAPAN: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 163
TABLE 134 JAPAN: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD MILLION) 163
12.5.3 CHINA 164
12.5.3.1 Healthcare infrastructure improvements to support market growth 164
TABLE 135 CHINA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 164
TABLE 136 CHINA: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD MILLION) 165
12.5.4 INDIA 165
12.5.4.1 Increasing patient population and rising number of surgical procedures to drive market 165
TABLE 137 INDIA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 166
TABLE 138 INDIA: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD MILLION) 166
12.5.5 AUSTRALIA 167
12.5.5.1 Rapid growth in sepsis treatment procedures to propel market 167
TABLE 139 AUSTRALIA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 167
TABLE 140 AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD MILLION) 168
12.5.6 SOUTH KOREA 168
12.5.6.1 Rising healthcare spending to support market growth 168
TABLE 141 SOUTH KOREA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 169
TABLE 142 SOUTH KOREA: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD MILLION) 169
12.5.7 REST OF ASIA PACIFIC 169
TABLE 143 REST OF ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 170
TABLE 144 REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD MILLION) 170
12.6 LATIN AMERICA 171
TABLE 145 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 171
TABLE 146 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 172
TABLE 147 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD MILLION) 172
TABLE 148 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 173
TABLE 149 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2022–2029 (USD MILLION) 173
TABLE 150 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2022–2029 (USD MILLION) 173
TABLE 151 LATIN AMERICA: BACTERIAL SEPSIS MARKET, BY TYPE, 2022–2029 (USD MILLION) 174
TABLE 152 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION) 174
TABLE 153 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 174
12.6.1 RECESSION IMPACT ON LATIN AMERICAN SEPSIS DIAGNOSTICS MARKET 175
12.6.2 BRAZIL 175
12.6.2.1 Investments by leading sepsis diagnostic manufacturers to support market growth 175
TABLE 154 BRAZIL: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 175
TABLE 155 BRAZIL: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD MILLION) 176
12.6.3 MEXICO 176
12.6.3.1 Rising medical tourism to drive market 176
TABLE 156 MEXICO: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 177
TABLE 157 MEXICO: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD MILLION) 177
12.6.4 REST OF LATIN AMERICA 177
TABLE 158 REST OF LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 178
TABLE 159 REST OF LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD MILLION) 178
12.7 MIDDLE EAST & AFRICA 179
12.7.1 HIGH CONSUMPTION OF IMMUNE SYSTEM-SUPPRESSING MEDICATIONS TO PROPEL MARKET 179
TABLE 160 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET, BY REGION, 2022–2029 (USD MILLION) 179
TABLE 161 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 180
TABLE 162 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD MILLION) 180
TABLE 163 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 181
TABLE 164 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2022–2029 (USD MILLION) 181
TABLE 165 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2022–2029 (USD MILLION) 181
TABLE 166 MIDDLE EAST & AFRICA: BACTERIAL SEPSIS MARKET, BY TYPE, 2022–2029 (USD MILLION) 182
TABLE 167 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION) 182
TABLE 168 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 182
12.7.2 RECESSION IMPACT ON MIDDLE EAST & AFRICAN SEPSIS DIAGNOSTICS MARKET 183
12.7.3 GCC COUNTRIES 183
12.7.3.1 Developments in healthcare infrastructure to drive market 183
TABLE 169 GCC COUNTRIES: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 183
TABLE 170 GCC COUNTRIES: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD MILLION) 184
12.7.4 REST OF MIDDLE EAST & AFRICA 184
TABLE 171 REST OF MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 184
TABLE 172 REST OF MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2022–2029 (USD MILLION) 185
13 COMPETITIVE LANDSCAPE 186
13.1 INTRODUCTION 186
13.2 RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS 186
FIGURE 31 SEPSIS DIAGNOSTICS MARKET: STRATEGIES ADOPTED 187
13.3 REVENUE SHARE ANALYSIS 188
FIGURE 32 REVENUE SHARE ANALYSIS OF KEY PLAYERS, 2020–2022 (USD MILLION) 188
13.4 MARKET SHARE ANALYSIS 188
13.4.1 SEPSIS DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023 189
FIGURE 33 SEPSIS DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023 189
TABLE 173 SEPSIS DIAGNOSTICS MARKET: DEGREE OF COMPETITION 189
13.4.2 BLOOD CULTURE MARKET SHARE, BY KEY PLAYER, 2023 190
FIGURE 34 BLOOD CULTURE MARKET SHARE, BY KEY PLAYER, 2023 190
13.4.3 IMMUNOASSAY MARKET SHARE, BY KEY PLAYER, 2023 190
FIGURE 35 IMMUNOASSAYS MARKET SHARE, BY KEY PLAYER, 2023 190
13.4.4 MOLECULAR DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023 191
FIGURE 36 MOLECULAR DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023 191
13.4.5 BIOMARKER MARKET SHARE, BY KEY PLAYER, 2023 191
FIGURE 37 BIOMARKERS MARKET SHARE, BY KEY PLAYER, 2023 191
FIGURE 38 SEPSIS DIAGNOSTICS MARKET RANKING (2023) 192
13.5 COMPANY EVALUATION MATRIX: KEY PLAYERS 193
13.5.1 STARS 194
13.5.2 EMERGING LEADERS 194
13.5.3 PERVASIVE PLAYERS 194
13.5.4 PARTICIPANTS 194
FIGURE 39 SEPSIS DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023 195
13.5.5 COMPETITIVE FOOTPRINT 196
13.5.5.1 Overall company footprint 196
FIGURE 40 SEPSIS DIAGNOSTICS MARKET: OVERALL COMPANY FOOTPRINT 196
13.5.5.2 Regional footprint 197
TABLE 174 SEPSIS DIAGNOSTICS MARKET: REGIONAL FOOTPRINT 197
13.5.5.3 Technology footprint 197
TABLE 175 SEPSIS DIAGNOSTICS MARKET: TECHNOLOGY FOOTPRINT 197
13.5.5.4 Product footprint 198
TABLE 176 SEPSIS DIAGNOSTICS MARKET: PRODUCT FOOTPRINT 198
13.5.5.5 Pathogen type footprint 199
TABLE 177 SEPSIS DIAGNOSTICS MARKET: PATHOGEN TYPE FOOTPRINT 199
13.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES 200
13.6.1 PROGRESSIVE COMPANIES 200
13.6.2 RESPONSIVE COMPANIES 200
13.6.3 DYNAMIC COMPANIES 200
13.6.4 STARTING BLOCKS 200
FIGURE 41 SEPSIS DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023 201
13.6.5 COMPETITIVE BENCHMARKING 202
TABLE 178 SEPSIS DIAGNOSTICS MARKET: DETAILED LIST OF KEY STARTUPS/SMES 202
TABLE 179 SEPSIS DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES 202
13.7 VALUATION AND FINANCIAL METRICS OF SEPSIS DIAGNOSTIC VENDORS 203
FIGURE 42 EV/EBITDA OF KEY VENDORS 203
FIGURE 43 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 203
13.8 PRODUCT/BRAND COMPARATIVE ANALYSIS 204
FIGURE 44 BRAND/PRODUCT COMPARATIVE ANALYSIS, BY MODEL (2023) 204
13.8.1 BIOMÉRIEUX 204
13.8.2 BECTON, DICKINSON AND COMPANY 204
13.8.3 F. HOFFMANN-LA ROCHE LTD. 205
13.8.4 DANAHER CORPORATION 205
13.8.5 QIAGEN N.V. 205
13.9 COMPETITIVE SCENARIO 205
13.9.1 PRODUCT LAUNCHES & APPROVALS 205
TABLE 180 SEPSIS DIAGNOSTICS MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2019–MARCH 2024 205
13.9.2 DEALS 206
TABLE 181 SEPSIS DIAGNOSTICS MARKET: DEALS, JANUARY 2019–MARCH 2024 206
13.9.3 EXPANSIONS 207
TABLE 182 SEPSIS DIAGNOSTICS MARKET: EXPANSIONS, JANUARY 2019–MARCH 2024 207
14 COMPANY PROFILES 209
(Business overview, Products offered, Recent Developments, MNM view)*
14.1 KEY PLAYERS 209
14.1.1 BIOMÉRIEUX 209
TABLE 183 BIOMÉRIEUX: COMPANY OVERVIEW 209
FIGURE 45 BIOMÉRIEUX: COMPANY SNAPSHOT (2022) 210
TABLE 184 BIOMÉRIEUX: PRODUCTS OFFERED 210
TABLE 185 BIOMÉRIEUX: PRODUCT LAUNCHES & APPROVALS 211
TABLE 186 BIOMÉRIEUX: DEALS 212
TABLE 187 BIOMÉRIEUX: OTHER DEVELOPMENTS 213
14.1.2 BECTON, DICKINSON AND COMPANY 214
TABLE 188 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW 214
FIGURE 46 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2023) 215
TABLE 189 BECTON, DICKINSON AND COMPANY: PRODUCTS OFFERED 215
TABLE 190 BECTON, DICKINSON AND COMPANY: PRODUCT LAUNCHES & APPROVALS 216
TABLE 191 BECTON, DICKINSON AND COMPANY: EXPANSIONS 217
14.1.3 DANAHER CORPORATION 219
TABLE 192 DANAHER CORPORATION: COMPANY OVERVIEW 219
FIGURE 47 DANAHER CORPORATION: COMPANY SNAPSHOT (2022) 220
TABLE 193 DANAHER CORPORATION: PRODUCTS OFFERED 220
TABLE 194 DANAHER CORPORATION: PRODUCT LAUNCHES & APPROVALS 221
TABLE 195 DANAHER CORPORATION: DEALS 221
14.1.4 T2 BIOSYSTEMS, INC. 223
TABLE 196 T2 BIOSYSTEMS INC.: COMPANY OVERVIEW 223
FIGURE 48 T2 BIOSYSTEMS INC.: COMPANY SNAPSHOT (2022) 223
TABLE 197 T2 BIOSYSTEMS, INC.: PRODUCTS OFFERED 224
TABLE 198 T2 BIOSYSTEMS, INC.: PRODUCT LAUNCHES & APPROVALS 224
TABLE 199 T2 BIOSYSTEMS, INC.: DEALS 225
TABLE 200 T2 BIOSYSTEMS, INC.: EXPANSIONS 225
14.1.5 DIASORIN S.P.A. 226
TABLE 201 DIASORIN S.P.A.: COMPANY OVERVIEW 226
FIGURE 49 DIASORIN S.P.A.: COMPANY SNAPSHOT (2022) 227
TABLE 202 DIASORIN S.P.A.: PRODUCTS OFFERED 227
TABLE 203 DIASORIN S.P.A.: PRODUCT LAUNCHES & APPROVALS 228
TABLE 204 DIASORIN S.P.A.: DEALS 228
14.1.6 F. HOFFMANN-LA ROCHE LTD. 229
TABLE 205 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW 229
FIGURE 50 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022) 230
TABLE 206 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS OFFERED 230
TABLE 207 F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES & APPROVALS 231
TABLE 208 F. HOFFMANN-LA ROCHE LTD.: DEALS 231
14.1.7 THERMO FISHER SCIENTIFIC INC. 233
TABLE 209 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 233
FIGURE 51 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2023) 234
TABLE 210 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED 234
TABLE 211 THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES & APPROVALS 235
TABLE 212 THERMO FISHER SCIENTIFIC INC.: EXPANSIONS 236
TABLE 213 THERMO FISHER SCIENTIFIC INC.: OTHER DEVELOPMENTS 236
14.1.8 BRUKER CORPORATION 237
TABLE 214 BRUKER CORPORATION: COMPANY OVERVIEW 237
FIGURE 52 BRUKER CORPORATION: COMPANY SNAPSHOT (2022) 238
TABLE 215 BRUKER CORPORATION: PRODUCTS OFFERED 238
TABLE 216 BRUKER CORPORATION: PRODUCT LAUNCHES & APPROVALS 239
TABLE 217 BRUKER CORPORATION: DEALS 240
14.1.9 QUIDELORTHO CORPORATION 241
TABLE 218 QUIDELORTHO CORPORATION: COMPANY OVERVIEW 241
FIGURE 53 QUIDELORTHO CORPORATION: COMPANY SNAPSHOT (2022) 242
TABLE 219 QUIDELORTHO CORPORATION: PRODUCTS OFFERED 242
14.1.10 SYSMEX CORPORATION 243
TABLE 220 SYSMEX CORPORATION: COMPANY OVERVIEW 243
FIGURE 54 SYSMEX CORPORATION: COMPANY SNAPSHOT (2023) 244
TABLE 221 SYSMEX CORPORATION: PRODUCTS OFFERED 244
TABLE 222 SYSMEX CORPORATION: PRODUCT LAUNCHES & APPROVALS 245
TABLE 223 SYSMEX CORPORATION: OTHER DEVELOPMENTS 245
14.1.11 ABBOTT LABORATORIES 246
TABLE 224 ABBOTT LABORATORIES: COMPANY OVERVIEW 246
FIGURE 55 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2023) 247
TABLE 225 ABBOTT LABORATORIES: PRODUCTS OFFERED 247
14.1.12 SIEMENS HEALTHINEERS 248
TABLE 226 SIEMENS HEALTHINEERS: COMPANY OVERVIEW 248
FIGURE 56 SIEMENS HEALTHINEERS: COMPANY SNAPSHOT (2023) 249
TABLE 227 SIEMENS HEALTHINEERS: PRODUCTS OFFERED 249
TABLE 228 SIEMENS HEALTHINEERS: PRODUCT APPROVALS 250
TABLE 229 SIEMENS HEALTHINEERS: DEALS 250
TABLE 230 SIEMENS HEALTHINEERS: EXPANSIONS 250
14.1.13 QIAGEN N.V. 251
TABLE 231 QIAGEN N.V.: COMPANY OVERVIEW 251
FIGURE 57 QIAGEN N.V.: COMPANY SNAPSHOT (2022) 252
TABLE 232 QIAGEN N.V.: PRODUCTS OFFERED 252
TABLE 233 QIAGEN N.V.: DEALS 253
TABLE 234 QIAGEN N.V.: EXPANSIONS 253
14.1.14 SEEGENE, INC. 254
TABLE 235 SEEGENE, INC.: COMPANY OVERVIEW 254
TABLE 236 SEEGENE, INC.: PRODUCTS OFFERED 254
14.1.15 PHC HOLDINGS CORPORATION 255
TABLE 237 PHC HOLDINGS CORPORATION: COMPANY OVERVIEW 255
TABLE 238 PHC HOLDINGS CORPORATION: PRODUCTS OFFERED 255
TABLE 239 PHC HOLDINGS CORPORATION: DEALS 256
14.2 OTHER PLAYERS 257
14.2.1 MCKESSON CORPORATION 257
TABLE 240 MCKESSON CORPORATION: COMPANY OVERVIEW 257
14.2.2 EKF DIAGNOSTICS HOLDINGS PLC 258
TABLE 241 EKF DIAGNOSTICS HOLDINGS PLC: COMPANY OVERVIEW 258
14.2.3 RESPONSE BIOMEDICAL CORP. 259
TABLE 242 RESPONSE BIOMEDICAL CORP.: COMPANY OVERVIEW 259
14.2.4 ALIFAX S.R.L. 259
TABLE 243 ALIFAX S.R.L.: COMPANY OVERVIEW 259
14.2.5 BODITECH MED INC. 260
TABLE 244 BODITECH MED INC.: COMPANY OVERVIEW 260
14.2.6 ADVANDX 260
TABLE 245 ADVANDX: COMPANY OVERVIEW 260
14.2.7 IMMUNEXPRESS INC. 261
TABLE 246 IMMUNEXPRESS INC.: COMPANY OVERVIEW 261
14.2.8 AXIS-SHIELD DIAGNOSTICS 261
TABLE 247 AXIS-SHIELD DIAGNOSTICS: COMPANY OVERVIEW 261
14.2.9 FUJIREBIO 262
TABLE 248 FUJIREBIO: COMPANY OVERVIEW 262
14.2.10 SEKISUI DIAGNOSTICS 262
TABLE 249 SEKISUI DIAGNOSTICS: COMPANY OVERVIEW 262
14.2.11 CURETIS GMBH 263
TABLE 250 CURETIS GMBH: COMPANY OVERVIEW 263
14.2.12 NANŌMIX INC. 263
TABLE 251 NANŌMIX INC.: COMPANY OVERVIEW 263
14.2.13 QVELLA CORPORATION 264
TABLE 252 QVELLA CORPORATION: COMPANY OVERVIEW 264
14.2.14 MOLZYM GMBH & CO. KG 264
TABLE 253 MOLZYM GMBH & CO. KG: COMPANY OVERVIEW 264
14.2.15 CYTOVALE, INC. 265
TABLE 254 CYTOVALE, INC.: COMPANY OVERVIEW 265
*Details on Business overview, Products offered, Recent Developments, MNM view might not be captured in case of unlisted companies.
15 APPENDIX 266
15.1 DISCUSSION GUIDE 266
15.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 270
15.3 CUSTOMIZATION OPTIONS 272
15.4 RELATED REPORTS 272
15.5 AUTHOR DETAILS 273
Table of Contents